Monday , November 29 2021

New results from Pfizer: Coronavirus vaccine is safe and 95% effective



[ad_1]

The companies said 162 of the 170 cases in Covid-19 were in the placebo group, and eight in the vaccine group. Nine out of 10 serious cases of Covid-19 received placebo.

Pfizer and BioNTech said the effectiveness of the vaccine was consistent across age, race, and ethnicity. The most serious adverse event was fatigue, with 3.7% of volunteers experiencing fatigue after taking the second dose. 2% of volunteers reported headaches after the second dose. Companies have reported that older adults have fewer and milder side effects.

“It’s pretty amazing,” Yale University immunologist Akiko Iwasaki said. He said the results were the most promising among those over 65. “We know from the flu vaccine that it’s very difficult to get protection in this age group with vaccines,” he said, so the 94 percent effectiveness in that group is “really remarkable.”

Federal health officials have said the first doses of vaccines are likely to target groups of health workers at high risk of exposure, as well as people who are most vulnerable to the disease, the elderly.

Dr. Saad B. Omer, director of the Yale Institute for Global Health, said the results of vaccines showing vaccines protected from serious disease are also good news, given the limited availability initially, the primary goal is not to stop transmission of the disease, but people very so as not to get sick. “So it’s very relaxing,” he said.

He asked Pfizer to publish a more detailed analysis of the data quickly – beyond the initial release – so that scientists can evaluate the results more accurately. The companies said they plan to submit the results for review in a scientific journal, a process that can take weeks or months. “These are not normal times, this is a pandemic and important policies are being pursued,” Dr. Omer said. “It’s always better to have a policy on scientific data, not a press release.”

In addition to the results of the clinical trial, Pfizer said it was willing to send the two-month safety data recommended by the agency to the FDA, as well as accurate manufacturing records that show the company can consistently create high-quality batches of its product. . The FDA will review the data and ask an outside panel of vaccine experts to review the application, a process that could take weeks.

[ad_2]
Source link